Pharmala Biotech Holdings Inc. (CSE:MDMA)
Canada · Delayed Price · Currency is CAD 0.1600
-0.0050 (-3.03%)
May 21, 2026, 3:59 PM EST
Pharmala Biotech Holdings Company Description
Pharmala Biotech Holdings Inc., doing business as PharmAla, focuses on the developing, manufacturing, and commercializing of substituted methylenedioxy-phenethylamines (MDXX) active pharmaceutical ingredients.
It also provides MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB); and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), as well as formulations of MDXX compounds.
The company is headquartered in Vancouver, Canada.
Pharmala Biotech Holdings Inc.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Nicholas Kadysh |
Contact Details
Address: 1055 West Georgia Street Vancouver, BC BC Canada |
Stock Details
| Ticker Symbol | MDMA |
| Exchange | Canadian Securities Exchange |
| Fiscal Year | September - August |
| Reporting Currency | CAD |
| ISIN Number | CA71719L1067 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Nicholas Kadysh | Director, President and Chief Executive Officer |
| Harpreet Kaur | Vice President of Research |
| William Edward Keith Avery C.A., CPA | Chief Financial Officer |
| Dr. Farnoud Kazemzadeh | Chief Operating Officer |
| Ali Taghva | Executive Officer |